-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 KV0K3suPdqbWcz566lqM6hlHJ0qA6F+2UJn/5jDxnGxDLdtTz7uChqV4ofNfeGoI
 TrrETCdikVSrle5+z6ukrQ==

<SEC-DOCUMENT>0001104659-10-057608.txt : 20101110
<SEC-HEADER>0001104659-10-057608.hdr.sgml : 20101110
<ACCEPTANCE-DATETIME>20101110165726
ACCESSION NUMBER:		0001104659-10-057608
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101110
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101110
DATE AS OF CHANGE:		20101110

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIO KEY INTERNATIONAL INC
		CENTRAL INDEX KEY:			0001019034
		STANDARD INDUSTRIAL CLASSIFICATION:	COMPUTER COMMUNICATIONS EQUIPMENT [3576]
		IRS NUMBER:				411761861
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-13463
		FILM NUMBER:		101180686

	BUSINESS ADDRESS:	
		STREET 1:		3349 HIGHWAY 138
		STREET 2:		BUIDING D, SUITE B
		CITY:			WALL
		STATE:			NJ
		ZIP:			07719
		BUSINESS PHONE:		6516870414

	MAIL ADDRESS:	
		STREET 1:		3349 HIGHWAY 138
		STREET 2:		BUIDING D, SUITE B
		CITY:			WALL
		STATE:			NJ
		ZIP:			07719

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SAC TECHNOLOGIES INC
		DATE OF NAME CHANGE:	19961115
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a10-20966_18k.htm
<DESCRIPTION>8-K
<TEXT>

<html>

<head>






</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<div style="border-bottom:solid windowtext 1.0pt;border-left:none;border-right:none;border-top:solid windowtext 3.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED
STATES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES
AND EXCHANGE COMMISSION</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington, D.C. 20549</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT
REPORT</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant
to Section&nbsp;13 or 15(d)&nbsp;of the Securities Exchange Act of 1934</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported): <b>November&nbsp;10,
2010</b></font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">BIO-key
International,&nbsp;Inc.</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact
name of registrant as specified in its charter)</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div align="center">

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State
  or other jurisdiction of<br>
  incorporation)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">1-13463</font></b></p>
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission
  File Number)</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="32%" valign="top" style="padding:0in 0in 0in 0in;width:32.0%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">41-1741861</font></b></p>
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(I.R.S.
  Employer Identification No.)</font></p>
  </td>
 </tr>
</table>

</div>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">3349 Highway 138, Building D, Suite&nbsp;B</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Wall, NJ 07719</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(732)&nbsp;359-1100</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check
the appropriate box below if the Form&nbsp;8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<i>see</i> General
Instruction A.2 below):</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications
pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant
to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement
communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17
CFR 240.14d-2(b))</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement
communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under Exchange Act (17 CFR
240.13e-4(c))</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="border-bottom:solid windowtext 3.0pt;border-left:none;border-right:none;border-top:solid windowtext 1.0pt;padding:1.0pt 0in 1.0pt 0in;">

<p style="border:none;margin:0in 0in .0001pt;padding:0in;text-autospace:none;"><font size="1" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>

</div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\106201\10-20966-1\task4353429\20966-1-ba.htm',USER='106201',CD='Nov 10 07:50 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 2.02.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Results of Operations and
Financial Condition.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
November&nbsp;10, 2010, BIO-key International,&nbsp;Inc. (the &#147;Company&#148;) issued
a press release announcing its financial results for its third quarter ended September&nbsp;30,
2010 which is included as an exhibit to a Current Report on Form&nbsp;8-K.&nbsp;A
copy of the press release issued by the Company on November&nbsp;10, 2010 is
attached as Exhibit&nbsp;99.</font></p>

<p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-indent:49.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The
information, including the exhibit attached hereto, in this Current Report on Form&nbsp;8-K
shall not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities
Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to
the liabilities of that Section, nor shall it be deemed incorporated by
reference in any filing under the Securities Act of 1933 or the Exchange Act,
except as otherwise expressly stated in such filing.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 9.01.</font></b><b><font size="1" style="font-size:8.5pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160; </font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">Financial Statements, Pro Forma
Financial Information and Exhibit.</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(d)</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Exhibits</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font><font size="1" style="font-size:8.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Press
Release, dated November&nbsp;10, 2010, issued by </font><font size="2" style="font-size:10.0pt;">the Company.</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2<a name="PB_2_072838_7748"></a></font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\106201\10-20966-1\task4353429\20966-1-ba.htm',USER='106201',CD='Nov 10 07:50 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this
report to be signed on its behalf by the undersigned hereunto duly authorized.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIO-KEY
  INTERNATIONAL,&nbsp;INC.</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date:
  November&nbsp;10, 2010</font></p>
  </td>
  <td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="50%" colspan="2" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
  </td>
  <td width="45%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:45.58%;">
  <p style="margin:0in 0in .0001pt 20.0pt;text-autospace:none;text-indent:-10.0pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/
  Cecilia C. Welch</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:45.58%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Cecilia C. Welch</font></p>
  </td>
 </tr>
 <tr>
  <td width="50%" valign="top" style="padding:0in 0in 0in 0in;width:50.0%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="4%" valign="top" style="padding:0in 0in 0in 0in;width:4.42%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="45%" valign="top" style="padding:0in 0in 0in 0in;width:45.58%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Chief Financial Officer</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3<a name="PB_3_072948_141"></a></font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\106201\10-20966-1\task4353429\20966-1-ba.htm',USER='106201',CD='Nov 10 07:50 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT&nbsp;INDEX</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="8%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:8.92%;">
  <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.76%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
  </td>
  <td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in 0in 0in 0in;width:88.34%;">
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:8.92%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.76%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
  <td width="88%" valign="top" style="border:none;padding:0in 0in 0in 0in;width:88.34%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  </td>
 </tr>
 <tr>
  <td width="8%" valign="top" style="padding:0in 0in 0in 0in;width:8.92%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p>
  </td>
  <td width="2%" valign="bottom" style="padding:0in 0in 0in 0in;width:2.76%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
  </td>
  <td width="88%" valign="top" style="padding:0in 0in 0in 0in;width:88.34%;">
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated November&nbsp;10, 2010, issued by the
  Company.</font></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4<a name="PB_4_073032_7608"></a></font></p>

<div style="margin:0in 0in .0001pt;text-autospace:none;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\106201\10-20966-1\task4353429\20966-1-ba.htm',USER='106201',CD='Nov 10 07:50 2010' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a10-20966_1ex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>

<html>

<head>






</head>

<body lang="EN-US">

<div style="font-family:Times New Roman;">

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Exhibit 99.1</font></b></p>

<p align="right" style="margin:0in 0in .0001pt;text-align:right;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
 <tr>
  <td width="75%" valign="top" style="padding:0in 0in 0in 0in;width:75.56%;">
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman"><img width="192" height="134" src="g209661mmi001.jpg" hspace="12"></font></p>
  </td>
  <td width="24%" valign="top" style="padding:0in 0in 0in 0in;width:24.44%;">
  <p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&nbsp;</font></i></b></p>
  <p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">NEWS RELEASE</font></i></b></p>
  </td>
 </tr>
</table>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIO-key&#174; Reports 2010 Third
Quarter and <br>
Nine-Month Financial Results</font></b></p>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Wall, NJ, November&nbsp;10, 2010</font></b><font size="2" style="font-size:10.0pt;"> &#151; BIO-key International,&nbsp;Inc. (OTC Bulletin Board: BKYI), a leader
in&#160; finger-based biometric identification
solutions, today reported financial results for the third quarter and
nine-month period ended September&nbsp;30, 2010.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total revenue for the three months ended September&nbsp;30,
2010 was $546,376 compared to $524,351 for the same period last year, an
increase of 4.2%.&#160; Driving this increase
were higher service and hardware revenue, offset by lower license revenue
compared to the prior year period.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gross profit and gross profit margin for the three
months ended September&nbsp;30, 2010 were $340,206 and 62.3% respectively, as
compared to $329,566 and 62.9% respectively, for the three months ended September&nbsp;30,
2009.&#160; The small decrease in gross profit
margin is directly attributable to higher hardware sales as a percentage of net
sales for the comparable period.&#160; The
Company believes that higher sales of its software as compared to hardware in
future periods will drive a significant increase in gross profit margins.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating expenses for the three months ended September&nbsp;30,
2010 were approximately $1.1 million, an increase of 8.8% as compared to
operating expenses of approximately $1.0 for the same period in 2009.&#160; This increase was primarily due to higher
selling, general and administrative (&#147;SG&amp;A&#148;) expenses related to higher
sales and marketing costs for customer visits and show exhibitions, in an
effort to expand the Company&#146;s customer base and revenues.&#160; Additionally, this increase was due to higher
administrative costs associated with the change in the Company&#146;s independent
auditors and an 8.3 % increase in research, development and engineering costs
directly related to consulting and hardware expenses on new projects.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating loss for the period ended September&nbsp;30,
2010 was ($742,824) compared to an operating loss of ($665,523) for the same
period in 2009. Total net loss including derivative and warrant fair value
adjustments and income from discontinued operations for the third quarter of
2010 was ($943,790) compared to a net loss of ($69,411) for the comparable 2009
period.&#160; Additionally, the 2009 third
quarter included $701,674 of income related to discontinued operations.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#147;We are disappointed with our third quarter
results, but remain highly optimistic about our market potential and our
future,&#148; stated Michael DePasquale, BIO-key&#146;s Chief</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105621\10-20966-1\task4354557\20966-1-mm.htm',USER='105621',CD='Nov 10 20:53 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Executive Officer.&#160;
&#147;There were a number of deals we anticipated would close, but were
delayed and as such, we believe our Q4 2010 results will show momentum in our
top-line and a return to gross profit margins that are more consistent with our
historical results.&#160; Demand for our
fingerprint biometric solutions remains strong and we continue to gain traction
in our markets; particularly in healthcare, as evidenced by our new contract
with The Institute for Transfusion Medicine, a new alliance with Medflow, and
continued integration of our software into Allscripts, Genesis Healthcare and
EPIC&#146;s biometric solution offerings.&#160;&#160; We
continue to explore other government and commercial opportunities, which if
successfully captured should positively impact our performance into next year.&#148;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Nine Month Comparisons</font></u></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Total revenue for the nine months ended September&nbsp;30,
2010 was approximately $3.0 million compared to approximately $1.3 million for
the same nine-month period last year, an increase of 120%. Driving this increase
were higher licensing sales to both new and existing customers, partially
offset by lower custom software service fees.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Gross profit and gross profit margin for the nine
months ended September&nbsp;30, 2010 were $2.5 million and 85.8% respectively,
as compared to $942,934 and 70.2% respectively, for the nine months ended September&nbsp;30,
2009.&#160; The increase in gross profit
margin is directly attributable to higher licensing fees as a percentage of net
sales for the comparable period.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Operating expenses for the nine months ended September&nbsp;30,
2010 were approximately $3.2, an increase of 1.5% as compared to operating
expenses of $3.2 million for the same period in 2009.&#160; Total SG&amp;A expenses declined by 2.4% as
the Company tooksteps to better align its overhead to support sales and
marketing initiatives, as well as lower legal and professional service fees and
charges for non-cash compensation.&#160; This
decline was partially offset by higher research, development and engineering expenses
and higher commission and referral fee expenses.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company reported an operating loss of
($704,926) compared to an operating loss of approximately ($2.3 million) for
the periods ended September&nbsp;30, 2010 and September&nbsp;30, 2009,
respectively. Accounting for income from derivative and warrant fair value
adjustments and income from discontinued operations, BIO-key&#146;s net income for
the nine month period ended September&nbsp;30, 2010 was $291,534 compared to
net income of $292,408 for the same period in&#160;
2009.&#160; Additionally, the 2010
nine-month period included approximately $400,000 of income related to
discontinued operations, compared with approximately $2.7 million for the same
nine-month period in 2009.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Liquidity and Capital Resources</font></u></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Consolidated cash, cash equivalents and accounts
receivables totaled over $2.4 million on September&nbsp;30, 2010, compared to
approximately $1.7 million as of December&nbsp;31, 2009.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105621\10-20966-1\task4354557\20966-1-mm.htm',USER='105621',CD='Nov 10 20:53 2010' -->


<br clear="all" style="page-break-before:always;">


<div style="font-family:Times New Roman;">

<p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Highlights for the third quarter included the
following:</font></p>

<p style="margin:0in 0in .0001pt .25in;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Ongoing orders from McKesson totaling
over $380,000.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Genesis Healthcare order in excess of
$90,000. This is the first solution sold with BIO-key integrated into EPIC EMR
(Epic is a software provider for mid-size and large healthcare organizations). BIO-key
now has an identity solution for the 225 customers (hospitals&nbsp;&amp;
clinics) and 200,000 physicians using EPIC products.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Jackson Madison County General Hospital,
TN purchased BIO-key product for integration into their ESSO.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Our existing relationship with IBM (BIO-key
is integrated into their TAM ESSO solution) is gaining momentum with several
new global opportunities being pursued.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Symbol" style="font-size:10.0pt;">&#183;</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">US Courts expanded their installation of
their enterprise SSO solution for use in<i>
Federal Probation and Pretrial Services Office</i>&#146;s fingerprint enabled
identity management system.</font></p>

<p style="margin:0in 0in .0001pt .5in;text-autospace:none;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">DePasquale continued, &#147;Through the first nine months
of the year, we more than doubled our revenue compared to the same period last
year.&#160; There continues to be significant
demand for biometric solutions across a number of industry verticals and waves
of consolidation persist.&#160; Our channel
partnerships remain strong and we are seeing increased interest in our
technology from health care, retail and financial services organizations, as
well as for our new mobility offering.&#160;
The market remains challenging due to macroeconomic conditions and
constraint on customers&#146; budgets, but we firmly believe we are well positioned for
both the near and long-term.&#148;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><u><font size="2" face="Times New Roman" style="font-size:10.0pt;">Conference Call Details</font></u></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIO-key has scheduled a call for Thursday
November&nbsp;11th at 10:00&nbsp;a.m. Eastern Time to discuss 2010 third
quarter results. To access the conference call live, dial 800-860-2442 and ask
for the BIO-key call at least 10 minutes prior to the start time.&nbsp; The
conference call will also be broadcast live over the Internet by logging onto
www.bio-key.com. A telephonic replay of the conference call will be available
through December&nbsp;11, 2010 and may be accessed by dialing 412-317-0088 and using
the pass code 446021#. A streaming audio replay of the webcast will be
available shortly after the call on the Company&#146;s website (www.bio-key.com) for
a period of thirty days.</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">About BIO-key</font></b></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">BIO-key International,&nbsp;Inc., headquartered in
Wall, New Jersey, develops and delivers advanced identification solutions to
commercial and government enterprises, integrators, </font></p>

<p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105621\10-20966-1\task4354557\20966-1-mm.htm',USER='105621',CD='Nov 10 20:53 2010' -->


<br clear="all" style="page-break-before:always;">


<div>

<p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">and custom application developers.&nbsp;BIO-key&#146;s
award winning, high performance, scalable, cost-effective and easy-to-deploy
biometric finger identification technology accurately identifies and
authenticates users of wireless and enterprise applications. Our solutions are
used in local embedded OEM products as well as some of the world&#146;s largest
identification deployments to improve security, guarantee identity, and help
reduce identity theft.&nbsp;&nbsp;BIO-key&#146;s technology is offered directly or
by market leading partners around the world. (http://www.bio-key.com)</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">BIO-key Safe Harbor Statement</font></b></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Certain statements contained in this press release
may be construed as &#147;forward-looking statements&#148; as defined in the Private
Securities Litigation Reform Act of 1995 (the &#147;Act&#148;).&nbsp; The words &#147;estimate,&#148;
&#147;project,&#148; &#147;intends,&#148; &#147;expects,&#148; &#147;anticipates,&#148; &#147;believes&#148; and similar
expressions are intended to identify forward-looking statements.&nbsp; Such
forward-looking statements are made based on management&#146;s beliefs, as well as
assumptions made by, and information currently available to, management
pursuant to the &#147;safe-harbor&#148; provisions of the Act.&nbsp; These statements are
subject to certain risks and uncertainties that may cause actual results to
differ materially from those projected on the basis of these statements.&nbsp;
These risks and uncertainties include, without limitation, our history of
losses and limited revenue, our ability to develop new products and evolve
existing ones, the impact on our business of the recent financial crisis in the
global capital markets and negative global economic trends, and our ability to
attract and retain key personnel.&nbsp; For a more complete description of
these and other risk factors that may affect the future performance of BIO-key
International,&nbsp;Inc., see &#147;Risk Factors&#148; in the Company&#146;s Annual Report on Form&nbsp;10-K
for the year ended December&nbsp;31, 2009 and its other filings with the
Securities and Exchange Commission.&nbsp; Readers are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of the
date made.&nbsp; The Company also undertakes no obligation to disclose any
revision to these forward-looking statements to reflect events or circumstances
after the date made or to reflect the occurrence of unanticipated events.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#169; Copyright 2010 by BIO-key International,&nbsp;Inc.</font></p>

<p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>

<div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>

</div>
<!-- SEQ.=1,FOLIO='',FILE='C:\JMS\105621\10-20966-1\task4354557\20966-1-mm.htm',USER='105621',CD='Nov 10 20:53 2010' -->


</body>

</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g209661mmi001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g209661mmi001.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``H'!P@'!@H("`@+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!#`0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P``1"`"&`,`#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#V7-&:**`#
M-&:*0D`$G@"@!<T9KD-?^(^DZ2S06A^WW*\;8CA%/NW^&:\]U?QUK^L%E>[-
MK"?^65O\HQ[GJ:PGB(1TW.^AE]:KK:R\SV+4->TG2A_IVH6\!_NLXW?EUKG;
MOXH^'K<D0?:;HC_GG'@?FV*\=)R2S')/4D\UHZ=X?UC5L?8=.GF4_P`>W"_F
M>*YGB9R^%'I1RNA35ZLOT.[F^+L7_+#1I#[R3`?R!J#_`(6[<?\`0&C_`._Y
M_P`*S[/X5Z[.`;F>UM0>Q8N?TX_6M:'X0IC]_K3Y](X`/YFFGB&2UEL-'K]X
MR/XO/G][HHQ_L3_XBM&U^+.CR$"YLKN#W`5Q^AJ$?"/3\<ZK=D_[BU!-\(8\
M?N-:<'TD@!_D:I?6$9/^S9=U]YU5AXU\.ZD0L&IQ*Y_@E_=G]:W%=74,I#*>
MA!R#7DEY\*=:A!-O<VER/[I)0_KQ68L/C#P@^]$O+6-3SC]Y$?J.15^VG'XX
MF;P5"I_!J+T?]?H>WYHS7G6@_%2&4K#K<`A)X^T0C*_BO4?AFN_M;J"]MTN+
M:9)HG&5=&R#6\*D9[,X*V'J47::)LT9HHJS`,T9HHH`,T9HHH`,T44"@`HHK
M+\0:]:>'M,>]NVR>D<8/S2-Z"DVDKLJ,7)J,=R76-:L-#L6N[^81H.%'5G/H
M!W->1>)O'6I>(&:"(M:6/:%&^9Q_M'O].E9.MZY?:_J#7E[)D](XQ]V-?051
MBBDGE2*)&DD<[511DL?05YU6NYNT=CZ3"8"%%<]367X(9P!Z"NE\.^!=6\0!
M9MOV2T/_`"WE'WA_LKW_`)5V'A+X<P62QWVMHL]S]Y;<\I']?[Q_2N]``&!P
M!T%72PU]9F&*S2SY:/W_`.1S6B^`M"T8*_V;[7<#_EK<?-S[#H*Z4`*````.
M@%+17;&*BK)'ASJ3J.\W<****H@**@N[RVL8#/=W$<$2]7D8**Y/4/BCH-HQ
M2V$]ZP[QKM7\S42G&.[-:=&I5^"-SLZ3J,=J\X_X6Q-.W^B:!)*/^NI8_HM6
M(_B=<Q\WGAJ\C7NR$_U45'MX=SH>`Q"WC^*-W6_`NAZT&=K86UP?^6UOA3GW
M'0UQ,FE^)_AY<M=V3_:]/)S)M!*$?[2_PGW%=GI?Q!\/:HXB%V;68\>7<C9S
M]>GZUTGRR+V96'U!%)PA/WHO7R*C7K4/<JJZ[/\`0Q_#?BBP\2V?G6K;)4'[
MV!C\R'^H]ZVJX/Q#X-N-,O/[?\+?N+J(EI+9/NN.^T?^R]^U=%X8\16_B33!
M<QCRYD.V>$GF-O\`#TJH2=^66YE6I1Y?:4OA_%>IM4445J<H4444`%`HH%`$
M5S<16EM)<3N(XHE+NQZ`"O"O%'B*?Q)J[W3Y6!,K!$?X%]?J>IKMOBGKQBMX
M=$@?YIAYD^/[H/"_B>?PKS"O/Q-2[Y$?0Y7AE&/MI;O84`D@`$D\`#O7K_@3
MP8FBVZZC?Q@ZA*N0#_RP4]A[^OY5S/PS\-KJ&H-J]U'N@M&Q$".&D]?P_F:]
M&O?$>AZ:=M[K%E;L.JR3J#^6:O#4OMLRS/%N_L8/U_R-+%+619^+?#FH2B&T
MURPFD/`1;A<G\,UKYQUKM/#"BJ1UG2@<'4[//_7=?\:GM[RUNPQM;F&<+][R
MI`V/RH`FKE?&/C6#PW']F@59]0D7*QD_+&/[S?X5U)KR'6O#=M_PE,]QK'B7
M38;268R/(]RHEVY^[M]<<>E957-+W#KPD:,IWK.R7XE*PTGQ#X^OS<3SLT2M
MAIY?]7'[*OK["O0M'^'F@Z6JM-;_`&Z<=9+CD9]EZ"M70[_09K..UT2]LYH8
MEPJ6\JM@?0&M6IA1C'5ZLNOCJE3W8>['LAD4$4"!(8DC4=%10!^E/HHK<X3.
MU'P_I&K1E+[3H)L_Q%`&'XCFL)='U7PF?.T:674-.',FGS-ET'K&W]#74W-U
M;V<#3W4\<$2_>DD<*H_$TL$\-U`D]O*DL4@W)(C!E8>H(J'!/7J:QK2BN5ZK
ML0:?J%MJEE'>6DF^*0<'&"#W!'8CTKE=?L7\+ZROBG3D/V=R$U*!!PRD_?`]
M1_GO6TUL-(UP7,`VVNH/LN$'19?X7'U^Z??%:\T,=Q`\,R!XY%*LIZ$'J*37
M,K/=%1FJ<KKX7^0L,J3PI-$X>.10RL.A!Z&GUSOA+S+!;S0)F+-ILN(6/5H6
MY0_AR/PKHJJ+NKF=2/+)H****H@*!10*`/GG5]1EU75[J^E))FE9@#_"N>!^
M55%1I'5$4LS$!0.Y/2O5=;^%UG?W;W6GWC6;2,6>-DWIDG/'0CZ58\,_#FTT
M6\6^O+G[9<1G,8V;40^N.YKS?J]1RU/IEF6'C2]W?L<S\1M#UG1/AY9+I>H?
M9K.R4?;HD8H\SL1SD=1DGBO./AYX1B\:^(WL+FZ>"&.%II&0`LV"!@9^M>W?
M%L?\6VU/_MG_`.C%KRKX,ZE9:/XDU"_U&Y2VMHK!M\CG@9=`*]%*RLCYN4G)
MN3W9H^/_`(16WAK09-9TF]GFCMR/.BGP2%)QD$`="1Q6A\'O%=WK(O/"6K32
M7$#VS&!V8[U7HR;NN,'(],4_XE_%+1-5\-SZ)HDKW4ET0LDVPJB*""<9Y).*
M;\$O!]];7DOB2^A>"%H3%:JXP9-Q!+8],#`]<TR3@/B%X;L_"GBV?2K&25X$
M1'4RD%AN&<9%>P_"GPMIF@^&(?$*S2^??VH>=I'PB*"3P/;U->:_&G_DHUS_
M`-<(O_0:[/6=4DTO]GVP$3;7NX([?(]&)+?H"/QH`Y#QS\2=6\7:H=,T>2:#
M3C)Y<44)(>X.<`MCGGLM='HGP&\^Q2;7-5DAN'&3#;H#L]BQZGZ"N:^"^F)J
M'CV.>5`RV4#SC/\`>X4?^A9_"OHR@#YX\:?"[5/!,(UG3+Z2ZM(F&Z5`8Y8#
MV)P>F>XKL_A1\2KC79?[!UN7S+U4+6]P>LP'56_V@.<]^:]+U"RBU+3KFQG4
M-%<1-&X/H1BOD_3[J?P]XE@N8V*S6-T#D?[+8/Y\T`?7-%-C<21K(O1@"/QI
MU`'SS\9=,U73O$:37VK27MO>EY+>)B0(%!^[CIWZBO6?A82?AOH^?^>;_P#H
M;5Y]^T!_R$=%_P"N,O\`-:Z#PSXVTKP9\,/#\NIK<,+E9%001[NCG.<D`=:`
M/1[RV%W;-"3MS@@^A!R#^8J>N%T3XN^'->U>WTNTAOUGN6VH7A&W/OACBM[Q
M/XPT7PE:+/JMSM:3/EPH-TDGT']3Q0`^YB^S^*K*[7@74#V\GN1\Z_R:MFO)
MI?CCX>NKNW\W2]11(9=ZNI0GH1R,^A-=%J'Q<\*Z?8VEXL]Q=QW8.WR(\E",
M9#`D8//2DE8J3ND=O17`:=\9O#&IZE;V$,.H+)<2+&A:$8!)P,X8FM#Q1\3-
M"\):H--U&.\><QB3]S$"H!Z<DBF2=?0*X_1?B;H6O6ES/91W8-L5#))$%+9!
M/!SC@*2?2NATK5X=51S&C1NGWD;!XR1D$=1D$?4&@"_1110!QOQ:_P"2;:I_
MVS_]&+7DWP>T:PU_7=2TW4H!/;2V)W(21R'0@@CH0:].^,>IV5KX$N[&:YC2
MYN]GDQ$_,^'4G`]`*\[^!4\<7C6XC>15:6R94!.-QW*<#\*`.B\;?!K2+30;
MG4=!:>&>TC,K0R/O610,D#/(.*P/A)X[U"QU^VT"]N'GT^[/EQ+(V3"_\.TG
ML>F/>O7?'.O6>@>$[^>[E57D@>*&,GF1V!``'XU\_?#33)]4\?:4D*%E@F$\
MC#^%5YR?T'XT`:GQH_Y*+<_]<(O_`$&ND\5P/+\`="D49$+0LWT.X?S(KFOC
M1_R46Y_ZX1?^@UZMX?T6+Q%\&[+292%%S8!58_PMG*G\"!0!YU\!YTC\8WD+
M'#2V3;?P937OU?*VB7]_X!\;17%U`Z3V,Q2>$\%E/#`?4'(/TKZ8T;7]+U^Q
M2\TR]BN(G&?E8;E]F'4&@#0)"@DG`')-?(6HM]MUVZ>+D3W+E,=\L<?SKZ`^
M)GQ`L/#^AW.GV=U'-JES&8TCC8$P@\%FQTXZ#UKRWX3^$9?$7BF*]FB)T_3W
M$LK$<,XY5/SY/L*`/2M>^+6F^$=4.ASZ;=7$MK%&)'1E`W%0<<_6LS_A?^E?
M]`.\_P"_JUWVI^#?#>LWK7NI:/;7-PP`:1UY('3-5/\`A6_@W_H7K/\`[Y/^
M-`'E'QDU>'7K;PUJMNCI%=6LDBJ_5<D<&LF3Q7-K7A+0O`VG[(59@ES--@`N
M9"5`/91D$G_)W_CM:V]C<Z#:6L*0P0VTBQQH,!0"N`*YO5?`TD7P_P!*\5V"
MNZ2(1>)G.P[R`X]N`#Z4`>\^$O!^F>$=)BM+2)&F`S-<LHWR-W.>P]!7S_JE
MW<^._B2$FE;;=WHMXQG_`%<6[``_#GZUZM\)O'W_``D6G#1-3ESJ5JGR.QYG
MC'?_`'AW_/UKQV]M'\,^.YK:],L*VUV0[Q\,(R?O+[[3D4`>D_$S6O!6F>&)
M/#&FVEM/>IM6/[.@_P!&(/)9_P"][=>>:I?"[P'J&H:/JW]L6K0:=J-L(X%E
M7YC)GB10>1CU[YKK_!OPT\*:+;QZNLZ:N[#S([N;'EJ.Q"]!]3^E;ND^/-`U
MOQ%/H6G7+7%Q`A<R*N8VQ@$!N^,B@#P[X?W[>#?B0EKJ4:J#*UG.7'W"3@,#
MVY`Y]#7;_&Z]^W7&C^&;.-)+RYE$A^4%@"=J#/49))_"L3XX^&_L&NV^OP)M
MBOALE([2J.#^*_R-2?"Z*]\8^.Y?$NKL)?[-@4!B,#?MVK^@)^M`'J5OX/L[
M7PS::-;;8?LR`>8$SYAVX;<.^[)K0T?1QI:N6D5W8!55%VI&@)(51DG&6/4U
MS6I_%'2+*[:WMK>>]"'#21D*I/L3UK9\-^+]-\3>8EKYD4\8W/#*,,!ZC'!%
M9JK!NR9T2PU:$.>478WJ***T.<YGQCX#TGQK!$+\RPSP`B*>(_,H/4$'@BO.
M;GX!W\4V_3_$$)`.5,L+(P_$$U[96;XCD>+PSJDL3LCI9RLK*<%2$."#0!Y/
M#\"=5NIU?5?$<;*.I1&D;'MN(KT3P]X$TGPOH]Q8:698YKJ,I+>D@S$XP"#V
MQG(`KAM0U7Q#%IO@>YTJYFFNAI\ES-"TC'[4$1&96_O$C.,UO>%[V'QKJ/B;
M9J%V+"X^RM"89V1H<QY(4C[IR,'%`'/S_`62YF::;Q1)*['EY+8LQ^I+UU_@
M/P#+X*-QNUN>_CF4*L++MCCP<Y`R>:S/A]I!DOM8O9M4U2=].U*>UA2:\=TV
M`8&Y3P3SUKG_``;%=ZG;V5S=6GBNY=[DAKN+4,6^!(1G:6S@8YX[&@#O_%O@
M#0_&,0:^B:*Z082ZAX<#T/8CV->;S_`7589V.GZ_;E#WDC9&Q^&:T/%.HQ0>
M-]?;4Y?$365I#`R?V7.R)!E>2_(`R<<_6K&K/XI3X=^&T.I.FK7.H(L<PFR6
M5MY0.R\-QMSVH`J:1\`XDG636=9,T8.3%;1[=W_`C_A7JNE:38:)I\=AIMLE
MM;1#Y40=_4GN?<UQ'A3Q1+XC\=(Y>2$IHY6ZLRQQ#<++M;*^OOZ&L*U\<D_$
M!=8;6XVTZYOFTX6'G?<C``6;;GC+@\^E`'L%%>;>)?#RKX[T6TCU?6(X=6DN
M'N$2_=0-J[@%'\(R>E79KNXTCX@O:Q7%Q-;V?AUI%ADE+;V5^&/JQ`Z]:`,K
MQ)\'+GQ'K=QJ,_B><K*Y:..6'?Y2G^$?,.!]*W?!7P^;PK9WME=ZO)J=G=)L
M^S21[8T'.<`D]<USL.GW]S\/7\;/XDU)=7,#7BLMP1`N"?W?E]-N!BCQ#XDU
MV/7_``_K%AYC(FCB^O+)6.V6/(WX7U`;(^E`$4GP)6'4VN]+\1S6:ART($)+
MQCT#!A^==/XF^&6F>*-.M4O+F8:C;0K$-0`!>7`_C'1O7^M5O"WBB`V/BS79
M+Q[BPM[QI82SD@1^6I"KZ<GIZUD_#3Q-._B!]/O]9347U:V%\BK-O^S2Y.Z+
MKQ\N#CVH`R$^!.K+FW/B:-;4GE5B?G_@.<5Z)X-\!Z1X+MG%D&FNI1B6YEQN
M8>@]![5#X%N[J[N?$@N;B680ZQ+'&'8G8H`PH]![5U9.`2!DT`>:?'#6K&U\
M*1Z1*BRW=[(KQ#O&JGE_Z?B:S;&V/@SX106_^KO]9;S).S!6&?T3`_&LBX\$
M^+_%WQ`&H^(M-:UL?.!D=I%*1PJ<A5Y]/YDT[QIKXU[7&>`_Z';#RK<#I@=6
M_'^6*PKSY8>IWX"A[6LF]EJ<_7<?"B!W\27,X!V1VA5C[EEP/T/Y5P_2O:?A
M[H;:/X<229-MQ>'SG!'('\(_+G\:XL/'FFGV/;S*JH4&NKT.JHHHKU#Y4*@O
MK./4+"XLIBPBN(FB?:<'##!Q^=3T4`8=KX2TZSFT:6)I]VBP-!;9<8*LH4[N
M.3@4[0_"NF>'+S4+G34>,ZC*)98RWRJ1G[H[#DUM4F,T`<SX2?1%GU>WTR2X
M$\EX\]W%<##J[<$@?W>*KV/PZL]-1(K+7M=@A1]ZPQWN$R3D\8Z$U'XP\/WD
M5VGB70"4U&W'[V-1_KD^G<X[=Q6CX5\867B6W"@B"]0?O;=CS]5]1_*LE/7E
MEN=,Z*</:4]5U\BMJRZ-X=U:^U2_M;R6/5XTBNI`GF0HJ@J`0.1D&FZ1X;\.
MW6C:=::=J4MW::?=B[M@)PQC89PO3.WD\&NK=%D0HZAE88*D9!KE=2^'6BWD
MIN+,S:9<'G?:MM&?]W_#%5+F6JU(@J4E:5T^^_X%W_A#-*37-0UF`S6]WJ-N
M;>=HF`&#C+`8X;@<U%)X!\.R>&QH/V)5@6,()E51-P<[M^.N:Q)/!/BVW^6R
M\72L@Z"1G!_F:J2^!/&%Y\MWXD#+WS-(?TXJ'4E_*;K#TG_R]7W,WM>F\-Z9
M>Z7J.I:D[7>DHZP(L@9Y-R[3N4=3@>U84?C3P[=>*5UB+3]4FOWMOLBQ*JLK
M)NW?=SUS4EC\)+=7#ZAJDDOJL*;<_B<FNRTCP[I6A1[=/LTB8C!D/+M]6/-)
M>UD^R*DL)3C97D_N1SD'PWT>Y@4-)JMKI\K^<^D&ZQ`&)S@J.V>P.*Z-M`L6
MUR#5]K":"U:U1`1Y?ED@XQCVK3HK<X#E(OASH4&C7FD0FYCLKVZ%S+$L@QD$
M'8./N\#BM"\\(Z/=7EA>1VRVD]A-YL3VJK&3Q@JV!R".U;=%`'*-\/K,7UW=
MVNM:U9F\G:>6.VN]B%SU.,5U*C:H7).!C)ZFAW6-"[L%51DDG``KS;QC\1@Z
MR:=H4G7Y9+L?R3_'\JB=2,%=F]##SKRY8(?\1/&2A)-"TV7+'Y;J53T']P>_
MK^5>:4O4Y/7UK:\,>&+OQ+?^5$#';1D>=.1PH]!ZGVKS)2E5D?44J=+"4M]%
MNS1\!>%FU[5!=W,?^@VK`MD<2/V7^IKV<#`Q573=.M=*L(K*SB$<,0PH]?<^
MI-6A7HTJ:IQL?-XO$O$5.;IT"BBBM3D"BBB@`HHHH`*X?Q9X#-Y<'5]"?[+J
M"'>R*VT2'U![-^AKN**B4%)69K2JSI2YH,\TT;XDW6G3G3_$UK(LD9VM,J8=
M?]Y>_P!17?Z=JUAJT`FL+N*X3_8;)'U'454UWPSI?B&'9?6X,@'R3)PZ?0_T
M-><ZI\/->T.<W6CSO=(O(:%MDJ_AW_"L6ZE/S1VJ.&Q&SY)?@>NT5XS:?$/Q
M/I4GD7;K<%."EU%A_P`Q@UO6OQ=3`%YH[@]S#,"/R(IK$4WOH*>6XB.ROZ,]
M(HKB(_BMH3#]Y;7L9_ZY@_UIY^*GAT#A+T_]L1_C5^VI]S#ZGB/Y&=I17`3_
M`!;TU1_H^F74I[;V5/\`&L:]^*^JS`K9V-O;#LSDR'^@J7B*:ZFD,OQ,OLV/
M5R0`2>`.YKF=<\?Z)HP:-9_MER/^64!S@^[=!7D^I^)-:UC(OM1FD0_\LU.U
M/R'%98'10.3T`K">*?V4>A1RE+6K+[C?\1>,M5\1$QS2>1:YXMXCA3_O'^*L
M#@5T.C>!M>UDJR6AMH#_`,MKCY1CV'4UZ+X?^'FDZ,5GN!]NNEY#RK\JGV7_
M`!S64:52J[LZZF+PV%CR0^Y'#^%O`%]KK)<WH>SL>NXC#RC_`&1V'N:];T_3
MK32[*.SLH5AAC&`J_P`SZGWJR*6NZG2C36AX.)Q=3$/WMNP4"B@5J<@4444`
M%%%%`!1110`4444`%&***`*E_I.GZI'LOK.&X'_31`2/H>U<Q??"[0+DEK<W
M%FQ_YYR;E_)LT45$H1ENC6G7JT_@DT8MQ\(903]EUA2.PEAQ^H-5#\)=6SQJ
M5F?P?_"BBN>=&">QZ=+&UVM9?@@_X5+J_P#T$;+\G_PJ:#X17A/^D:O"H_Z9
MQ$_S(HHJ8T8-[%5,;72TE^"-BS^%&CPD&[N[JZ([`A!^G/ZUTNF^&=&TG!LM
I.@B8?Q[=S?F>:**Z8TX1V1YE3$UJGQ2;-3%%%%:&`4444`%%%%`'_]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
